Showing results for isu fsgs
President Obama signed the appropriations package to fund federal agencies through fiscal year 2015 (ending September 30, 2015). This includes allocations for NIH and other health care funding agencies such … Read more
KING OF PRUSSIA, Pa. (MAY 2, 2023) — Travere Therapeutics announced Monday results from their Phase 3 DUPLEX Study, which tests the drug sparsentan in focal segmental glomerulosclerosis (FSGS) patients. … Read more
Not too long ago, the Liposorber LA-15 System was approved by the FDA for use in pediatric FSGS patients that have tricky cases. This unique device offers a different type … Read more
NephCure’s Nurse Kristen Hood and Kylie Winkler discuss Travere’s Therapeutics achievement of interim proteinuria endpoint in the ongoing Phase 3 DUPLEX study of Sparsentan in Focal Segmental Glomerulosclerosis (FSGS). Learn … Read more
FSGS Diagram
FSGS Vid Sample
By Nephron – Own work, CC BY-SA 3.0
NephCure is a registered non-profit (501c3) tax-exempt charitable organization. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. All rights reserved worldwide. NephCure, and the logo, are federally registered trademarks of NephCure, Inc.
EN 
ES 
